Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates

Yao, Yuqin; Lin, Yan‐Hui; Su, Xiaolan; Wang, Yuxi; Li, Wenting; Wu, Yangpin; Cheng, Xiangzheng; Zhang, Hang; Wei, Xian; Chen, Hao; Zhang, Rundong; Gou, Lantu; Chen, Xiaoxin; Xie, Yongmei; Zhang, Bo; Zhang, Yonghui; Yang, Jinliang; Wei, Yuquan

doi:10.1016/j.jconrel.2015.09.058

Cited by 34 publications

(17 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, according to Yao et al . () trastuzumab‐SN38 conjugates may have encouraging activity in HER2‐positive ovarian cancer.…”

Section: Resultsmentioning

confidence: 99%

“…As for attaching cytotoxic drugs to monoclonal antibodies, that is, antibody-drug conjugates (ADCs) of irinotecan attached to bevacizumab, results of clinical phase II studies also show that they have great potential for recurrent ovarian cancer (Muggia et al, 2013;Musa et al, 2017). In addition, according to Yao et al (2015) trastuzumab-SN38 conjugates may have encouraging activity in HER2-positive ovarian cancer. The topoisomerase II inhibitor epirubicin, a 4 0 -epiisomer of the anthracycline antibiotic doxorubicin (epirubicin, NSC256942), is also ranked highly in our prioritized list of ovarian cancer drugs.…”

Section: Prioritization Of Drugs For Ovarian Cancermentioning

confidence: 99%

See 1 more Smart Citation

Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities

Zheng

Kong

et al. 2019

Molecular Oncology

View full text Add to dashboard Cite

Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed prioritization of candidate drugs (PriorCD), for the prioritization of candidate cancer drugs based on a global network propagation algorithm and a drug–drug functional similarity network constructed by integrating pathway activity profiles and drug activity profiles. This provides a new approach to drug repurposing by first considering the drug functional similarities at the pathway level. The performance of PriorCD in drug repurposing was evaluated by using drug datasets of breast cancer and ovarian cancer. Cross‐validation tests on the drugs approved for the treatment of these cancers indicated that our approach can achieve area under receiver‐operating characteristic curve (AUROC) values greater than 0.82. Furthermore, literature searches validated our results, and comparison with other classical gene‐based repurposing methods indicated that our pathway‐level PriorCD is comparatively more effective at prioritizing candidate drugs with similar therapeutic effects. We hope that our study will be of benefit to the field of drug discovery. In order to expand the usage of PriorCD, a freely available R‐based package, PriorCD, has been developed to prioritize candidate anticancer drugs for drug repurposing.

show abstract

“…In addition, according to Yao et al . () trastuzumab‐SN38 conjugates may have encouraging activity in HER2‐positive ovarian cancer.…”

Section: Resultsmentioning

confidence: 99%

Section: Prioritization Of Drugs For Ovarian Cancermentioning

confidence: 99%

Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities

Zheng

Kong

et al. 2019

Molecular Oncology

View full text Add to dashboard Cite

show abstract

“…Besides the specific upregulation in several human cancers, the monoclonal antibody binds to HAVCR1 can be internalized into the cells, making it an attractive target for antibody-mediated therapy, such as antibody-drug conjugates (ADCs) in certain cancers [ 21 – 23 ]. In this study, we observed that HAVCR1 upregulation was associated with poor responses to primary therapy.…”

Section: Discussionmentioning

confidence: 99%

HAVCR1 expression might be a novel prognostic factor for gastric cancer

et al. 2018

View full text Add to dashboard Cite

Hepatitis A virus cellular receptor 1 (HAVCR1), which is also known as T-cell immunoglobulin and mucin domain 1 (TIM-1) is a TIM gene family member. In this study, we aimed to characterize the expression profile of HAVCR1 in GC, its prognostic value and the potential epigenetic mechanism leading to its dysregulation. Bioinformatic analysis was performed by using genomic, clinicopathological and survival data in the human protein atlas (HPA) and the Cancer Genome Atlas (TCGA). Results showed that HAVCR1 was significantly upregulated at the mRNA and protein level in GC tissues compared to the adjacent normal tissues. In addition, HAVCR1 upregulation was an independent indicator of shorter OS (HR: 1.698, 95%CI: 1.221–2.361, p = 0.002), after adjustment of older age, differentiation status, pathological stages and the presence of residual tumor and was also an independent indicator of shorter RFS (HR: 2.577, 95%CI: 1.583–4.197, p<0.001), after adjustment of gender and histological grade. The methylation level of two CpG sites (cg11188031 and cg07320595) was negatively correlated with HAVCR1 expression. However, only high methylation level of cg07320595 was associated with significantly longer OS (p = 0.018) and RFS (p = 0.021). Based on these findings, we infer that HAVCR1 upregulation might serve as a valuable prognostic marker in terms of OS and RFS in GC patients. Cg07320595 might be a critical CpG site influencing HAVCR1 expression.

show abstract

“…The linkers basing on pyrophosphate diester and quaternary ammonium have been developed to create site‐specific ADCs. Yao et al investigated the influence of linkers on the therapeutic effect of ADCs . Three linkers including hydrophobic linker with cleavable ester bond, hydrophobic linker with cleavable carbonate bond, and hydrophilic linker with cleavable carbonate bond were used, which connected trastuzumab with 7‐ethyl‐10 hydroxycamptothecin (SN38) for curing human epidermal growth factor receptor 2 (Her2)‐positive SKOV3 ovarian tumor in subcutaneous xenograft model.…”

Section: Positive Targetingmentioning

confidence: 99%

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Qin

Zhang

2018

Small

109

View full text Add to dashboard Cite

Efficacy and safety of chemotherapeutic drugs constitute two major criteria in tumor chemotherapy. Nanomedicines with tumor-targeted properties hold great promise for improving the efficacy and safety. To design targeted nanomedicines, the pathological characteristics of tumors are extensively and deeply excavated. Here, the rationale, principles, and advantages of exploiting these pathological characteristics to develop targeted nanoplatforms for tumor chemotherapy are discussed. Homotypic targeting with the ability of self-recognition to source tumors is reviewed individually. In the meanwhile, the limitations and perspective of these targeted nanomedicines are also discussed.

show abstract

Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates

Cited by 34 publications

References 45 publications

Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities

Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities

HAVCR1 expression might be a novel prognostic factor for gastric cancer

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Contact Info

Product

Resources

About